Latest News

Events

BIO CEO & Investor Conference, New York
Feb 8-9, 2016

EASL – Barcelona,
April 13-17, 2016


welcome

We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat liver diseases where there is high unmet medical need, such as rare cholestatic diseases and nonalcoholic steatohepatitis (NASH), and debilitating gastrointestinal disorders.

Our clinical pipeline includes three Phase 2 or later-stage product candidates that are designed to act locally to restore normal bile acid levels and treat diseases and disorders associated with irregularities in bile acid biology.


blockbuster-portfolio
portfolio5
portfolio1
portfolio2
portfolio4